NASDAQ:MNOV

MediciNova Q4 2025 Earnings Results & Report

MediciNova logo
$1.28 -0.05 (-3.83%)
As of 02:56 PM Eastern
This is a fair market value price provided by Massive. Learn more.

MediciNova beat analyst earnings expectations in its Q4 2025 results, released February 20, 2026. The company reported EPS of -$0.05 versus the -$0.0950 consensus estimate, while revenue was $151.74 thousand.

Earnings Announcement Details

Quarter
Q4 2025
Time
Before Market Opens
Conference Call
7:00 AM ET

MediciNova EPS Results

Actual EPS
-$0.05
Consensus EPS
-$0.0950
Beat/Miss
Beat by +$0.0450
One Year Ago EPS
N/A
EPS Beat Rate
6 of last 8 quarters

MediciNova Revenue Results

Actual Revenue
$151.74 thousand
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

MediciNova Q4 2025 Earnings FAQ

MediciNova (NASDAQ:MNOV) reported earnings of -$0.05 per share for Q4 2025, beating the consensus estimate of -$0.0950. The report was announced on Friday, February 20, 2026.

MediciNova reported revenue of $151.74 thousand for Q4 2025.

MediciNova Earnings Headlines

Medicinova Inc
MediciNova to Participate in the Maxim Growth Summit
CFA: Bank of America Said THIS
On January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savings account… The digital dollar is inevitable. Think about what this means... When the digital dollar goes live, every dollar you saved could suddenly be trackable at the transaction level. Imagine the worst case scenario: You’re now subject to new digital withdrawal limits and spending restrictions. Your account can be frozen remotely without court approval. But here's what Bank of America didn't say: There's still a way to protect your wealth before this digital prison locks. While everyone else gets trapped in the digital system, my research team has been positioning members outside that reach… completely under their own control. No government tracking. No withdrawal limits. No remote freezing.tc pixel
MediciNova stock tumbles on mixed Phase 2 NAFLD trial data
See More MediciNova Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like MediciNova? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MediciNova and other key companies, straight to your email.

About MediciNova

MediciNova (NASDAQ:MNOV) is a clinical-stage biopharmaceutical company that develops small-molecule drug candidates for neurological, pulmonary and other conditions. The company is based in La Jolla, California, and conducts research and clinical development through collaborations and studies in the United States and other countries.

Its lead candidate, MN-166 (ibudilast), is being studied for several conditions, including amyotrophic lateral sclerosis, progressive multiple sclerosis and substance use disorders. MediciNova is also developing MN-001 (tipelukast) for potential uses in metabolic and fibrotic diseases. These candidates are investigational and have not been approved as medicines.

MediciNova was founded in 2000. Yuichi Iwaki, M.D., Ph.D., is the company’s founder, president and chief executive officer.

View MediciNova Profile